189 related articles for article (PubMed ID: 38111587)
41. Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6
Li X; Gao Z; Chen J; Feng S; Luo X; Shi Y; Tang Z; Liu W; Zhang X; Huang A; Gao Q; Ke A; Zhou J; Fan J; Fu X; Ding Z
Front Oncol; 2023; 13():1099385. PubMed ID: 37593098
[TBL] [Abstract][Full Text] [Related]
42. Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation.
Gou Q; Liu Z; Xie Y; Deng Y; Ma J; Li J; Zheng H
Front Pharmacol; 2022; 13():995555. PubMed ID: 36225561
[No Abstract] [Full Text] [Related]
43. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
44. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
45. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.
Kang K; Wu Y; Han C; Wang L; Wang Z; Zhao A
Comput Biol Med; 2023 May; 158():106836. PubMed ID: 37031511
[TBL] [Abstract][Full Text] [Related]
46. Development of a CD8
Dai YW; Wang WM; Zhou X
Heliyon; 2023 Sep; 9(9):e19798. PubMed ID: 37810147
[TBL] [Abstract][Full Text] [Related]
47. The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer.
Huang J; Xu Y; Qi S; Zheng Q; Cui C; Liu L; Liu F
Discov Oncol; 2024 Jun; 15(1):202. PubMed ID: 38822944
[TBL] [Abstract][Full Text] [Related]
48. A novel eight-gene Immune Cell-Associated Predictive Gene model to predict recurrence in triple-negative breast cancer.
Sui XY; Shao ZM; Fan L
Transl Cancer Res; 2023 Jul; 12(7):1727-1740. PubMed ID: 37588732
[TBL] [Abstract][Full Text] [Related]
49. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
[TBL] [Abstract][Full Text] [Related]
50. Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome.
Wang P; Fu Y; Chen Y; Li Q; Hong Y; Liu T; Ding Z
Biomed Res Int; 2020; 2020():4029062. PubMed ID: 33299869
[TBL] [Abstract][Full Text] [Related]
51. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
52. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
[TBL] [Abstract][Full Text] [Related]
53. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
[TBL] [Abstract][Full Text] [Related]
54. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.
Qiu P; Guo Q; Pan K; Chen J; Lin J
Front Oncol; 2022; 12():890242. PubMed ID: 36276158
[TBL] [Abstract][Full Text] [Related]
55. Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer.
Luo H; Hong R; Xu Y; Zheng Q; Xia W; Lu Q; Jiang K; Xu F; Chen M; Shi D; Deng W; Wang S
Gland Surg; 2023 Feb; 12(2):225-242. PubMed ID: 36915811
[TBL] [Abstract][Full Text] [Related]
56. Four-lncRNA immune prognostic signature for triple-negative breast cancer Running title: Immune lncRNAs predict prognosis of TNBC.
Li YX; Wang SM; Li CQ
Math Biosci Eng; 2021 May; 18(4):3939-3956. PubMed ID: 34198419
[TBL] [Abstract][Full Text] [Related]
57. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
59. Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.
Ding MR; Qu YJ; Peng X; Chen JF; Zhang MX; Zhang T; Hu B; An HM
BMC Cancer; 2022 Jun; 22(1):611. PubMed ID: 35658846
[TBL] [Abstract][Full Text] [Related]
60. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
